Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol
Antonio Molino,1,* Giovanna Calabrese,1,* Mauro Maniscalco2 1Division of Pneumology, Department of Respiratory Diseases, University of Naples Federico II, AORN dei Colli-Monaldi Hospital, Naples, Italy; 2Pulmonary Rehabilitation Division, ICS Maugeri SpA SB, Institute of Telese Terme, Telese Terme,...
Main Authors: | Molino A, Calabrese G, Maniscalco M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-06-01
|
Series: | Patient Preference and Adherence |
Subjects: | |
Online Access: | https://www.dovepress.com/-focus-on-the-new-combination-patient-considerations-in-the-treatment-peer-reviewed-article-PPA |
Similar Items
-
Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy
by: Lal C, et al.
Published: (2016-12-01) -
Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
by: Peter R. Bremner, et al.
Published: (2018-01-01) -
Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy
by: Moretz C, et al.
Published: (2020-10-01) -
The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population
by: Kato M, et al.
Published: (2019-12-01) -
Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model
by: Wilson MR, et al.
Published: (2017-03-01)